RxDoctor Payments Data

Channing Broyan

Physician Assistant · Wilmington, NCNPI 1952719205

Payments from drug & device makers

$8,803in general payments, 2019–2025

Across 227 payments — averaging $38.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sun Pharmaceutical Industries Inc.$964
  • Regeneron Healthcare Solutions, Inc.$717
  • Lilly USA, LLC$698
  • Johnson & Johnson$684
  • Incyte Corporation$681
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$8,24594%
  • Education$5586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,803 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,008
Medicare patients
382
Services billed
1,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$123,651
Dupixent PenDupilumab11$47,348
Fluorouracil71$4,431
Tacrolimus35$4,371
Ketoconazole156$2,393
Metronidazole19$2,229
Ciclopirox40$1,186
CiclopiroxCiclopirox Olamine32$1,090
Clobetasol Propionate25$930
Tretinoin11$650
Doxycycline Hyclate29$317
Triamcinolone Acetonide52$310
Mupirocin16$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$392$123,65120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →